Results 261 to 270 of about 236,269 (292)
Some of the next articles are maybe not open access.
Minimal residual disease in gastrointestinal cancer
Seminars in Surgical Oncology, 2001AbstractTumor progression after curative resection of gastrointestinal carcinomas is probably caused by pre‐ or intraoperative tumor cell dissemination. Disseminated tumor cells are generally detected by immunohistochemistry‐ or PCR‐based molecular‐biology methods. A consensus on which is the most adequate detection method has not yet been found, which
P, Kienle, M, Koch
openaire +2 more sources
Advances in the detection of minimal residual disease
Current Opinion in Hematology, 1997The study of minimal residual disease (MRD) is an attempt to detect and define the significance of leukemia invisible to normal morphologic examination. In many circumstances the clinical significance of MRD detection is unclear, because the technical ability to detect and quantify it has outpaced studies demonstrating its clinical significance.
J, Radich, B, Thomson
openaire +2 more sources
2009
During the past 30 years, survival rates after allogeneic stem cell transplantation (SCT) have been improved substantially. These improvements have mostly been due to better graft matching using genomic HLA typing, GVHD prophylaxis, infection management, and supportive care [1-3]. The incidence of leukemia relapse and death rates after relapse, however,
openaire +1 more source
During the past 30 years, survival rates after allogeneic stem cell transplantation (SCT) have been improved substantially. These improvements have mostly been due to better graft matching using genomic HLA typing, GVHD prophylaxis, infection management, and supportive care [1-3]. The incidence of leukemia relapse and death rates after relapse, however,
openaire +1 more source
Minimal Residual Disease in Leukemia in Children
Annals of the New York Academy of Sciences, 1997Many chromosomal translocations involved in leukemia have been defined at the molecular level in recent years. In addition to advancing the understanding of pathological mechanisms underlying the transformation process, the cloning and sequencing of the genes altered by the translocations have provided new tools for diagnosis and monitoring of patients.
B, Kornhuber +3 more
openaire +2 more sources
Minimal residual disease in leukaemia patients
The Lancet Oncology, 2001Because of developments in diagnosis of haemopoietic malignant diseases during the past two decades, routine and reliable identification of very low numbers of malignant cells, known as minimal residual disease (MRD), is now possible. Several large-scale studies have shown that monitoring of MRD in haemopoietic malignant disease predicts clinical ...
Szczepanski, Tomek +4 more
openaire +2 more sources
Detection of minimal residual disease in ALL
1993Complete remission (CR) of acute leukemia is defined in clinical practice as the presence in the bone marrow of less than 5% blast cells, a level determined by the limits of reliable detection by morphology. Mathematical models predict that the level of residual disease during clinical remission could vary from 1010 leukemic cells following early ...
M, Deane, A V, Hoffbrand
openaire +2 more sources
Minimal Residual Disease in Prostate Cancer
2018Detection of minimal residual disease (MRD) in prostate cancer over several decades has greatly informed our understanding of dissemination and recurrence, but has not yet been routinely used in clinical care. Investigators have detected MRD by identification of prostate cancer cells in the bone marrow; termed disseminated tumor cells (DTCs) and blood;
Frank C, Cackowski, Russell S, Taichman
openaire +2 more sources
Multiple Myeloma Minimal Residual Disease
2016Assessment of minimal residual disease (MRD) is becoming standard diagnostic care for potentially curable neoplasms such as some acute leukemias as well as chronic myeloid and lymphocytic leukemia. Although multiple myeloma (MM) remains as an incurable disease, around half of the patients achieve complete remission (CR), and recent data suggests ...
Bruno, Paiva +2 more
openaire +2 more sources
Monitoring minimal residual disease in AML
Cytotherapy, 1999There have been a number of publications that describe the clinical monitoring of acute leukemia patients for residual leukemia cells. Almost all of them have been focused on ALL. The phenotype of ALL appears to be quite stable. In contrast, the relapse phenotype for AML is almost always different from the phenotype found in the diagnostic specimen ...
openaire +2 more sources
Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact
Cancers, 2021Rachel Galot +2 more
exaly